1 week Ago By Defense World Staff
Norges Bank purchased a new position in Terns Pharmaceuticals, Inc. ( NASDAQ:TERN – Free Report ) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 849,389 shares of the company’s stock, valued at approximately $4,706,000.
Norges Bank owned 1.00% of Terns Pharmaceuticals at the end of the most recent quarter. Several other institutional investors and hedge funds also recently bought and sold shares of TERN.
Rhumbline Advisers increased its stake in shares of Terns Pharmaceuticals by 16.0% in the fourth quarter. Rhumbline Advisers now owns 97,892 shares of the company’s stock worth $542,000 after purchasing an additional 13,479 shares in the last quarter.
Charles Schwab Investment Management Inc. increased its stake in Terns Pharmaceuticals by 1.3% in the 3rd quarter.
Charles Schwab Investment Management Inc. now owns 154,714 shares of the company’s stock worth $1,290,000 after buying an additional 1,994 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Terns Pharmaceuticals by 191.
9% during the third quarter. The Manufacturers Life Insurance Company now owns 66,100 shares of the company’s stock valued at $551,000 after acquiring an additional 43,455 shares during the period. Geode Capital Management LLC lifted its position in shares of Terns Pharmaceuticals by 7.
6% in the third quarter. Geode Capital Management LLC now owns 1,207,479 shares of the company’s stock valued at $10,072,000 after acquiring an additional 85,617 shares in the last quarter. Finally, Savant Capital LLC purchased a new stake in shares of Terns Pharmaceuticals during the fourth quarter worth about $89,000.
98.26% of the stock is currently owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth Separately, William Blair restated a “market perform” rating on shares of Terns Pharmaceuticals in a research note on Friday, March 21st.
Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $18.38.
Terns Pharmaceuticals Trading Up 12.2 % Shares of TERN stock opened at $2.30 on Thursday.
The stock’s 50-day moving average price is $3.46 and its 200-day moving average price is $5.38.
Terns Pharmaceuticals, Inc. has a 12-month low of $1.87 and a 12-month high of $11.
40. The stock has a market capitalization of $200.79 million, a price-to-earnings ratio of -1.
95 and a beta of -0.13. Terns Pharmaceuticals ( NASDAQ:TERN – Get Free Report ) last announced its quarterly earnings results on Thursday, March 20th.
The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.
06. As a group, research analysts predict that Terns Pharmaceuticals, Inc. will post -1.
19 EPS for the current fiscal year. Terns Pharmaceuticals Profile ( Free Report ) Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
See Also Five stocks we like better than Terns Pharmaceuticals How to Invest in Insurance Companies: A Guide Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore What Are Earnings Reports? Are Tariffs Threatening Disney’s Comeback Story? 3 Home Improvement Stocks that Can Upgrade Your Portfolio Is Alphabet a Generational Buying Opportunity at These Levels? Want to see what other hedge funds are holding TERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Terns Pharmaceuticals, Inc.
( NASDAQ:TERN – Free Report ). Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
